At a glance
ClinicalIndex Comparison RecordN/ACompleted· 185 enrolled / 185 target
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Palbociclib Combinations in HR+/HER2- Metastatic Breast Cancer Patients: A Non-Interventional Prospective Study on the Treatment Patterns & Clinical Outcomes in Africa Middle East (PRECIOUS)
In Brief
An observational study for Metastatic Breast Cancer. Completed, enrolled 185 participants across 12 sites in 5 countries.
Signals
Enrolling slower than its timeline implies
Detailed Summary
The objective of this non-interventional multicenter study is to provide prospective, observational data on patients initiating treatment with palbociclib combination to contribute to the knowledge of HR+ HER2-metastatic/locally advanced Breast Cancer (BC) disease management, its treatment pattern, clinical outcomes and quality of life (QoL) in the routine clinical practice in Africa and Middle East countries .
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Breast Cancer
CountriesEgypt, Jordan, Lebanon, Qatar, Saudi Arabia
Collaborators--
Timeline
N/ACompletedFinished
20222023202420252026
First PostedJun 2021
Enrollment StartJul 2021
Primary CompletionApr 2025
TodayJul 2026
First PostedJun 24, 2021
Enrollment StartJul 15, 2021
Primary CompletionApr 29, 2025
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 5.0 years ago